Related Experiment Video

Updated: Jun 20, 2026

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
09:16

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy

Published on: September 11, 2015

Beyond thermodynamics: drug binding kinetics could influence epidermal growth factor signaling

Mayank Goyal1, Michael Rizzo, Frank Schumacher

  • 1Department of Chemistry and Biochemistry and the Center for Nanoscience, University of Missouri-Saint Louis, One University Boulevard, St. Louis, Missouri 63121, USA.

Journal of Medicinal Chemistry
|August 26, 2009
PubMed

Insights

Drug binding kinetics significantly impact therapeutic potential in non-small-cell lung cancer EGFR pathway targets. Fast binding is generally beneficial, but exceptions and pathway enhancement effects exist, influencing drug efficacy metrics like IC50.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Oncology

Background:

  • The Epidermal Growth Factor Receptor (EGFR) signaling pathway is crucial in non-small-cell lung cancer (NSCLC) pathogenesis.
  • Understanding drug interactions with protein kinases in this pathway is vital for developing effective cancer therapies.

Purpose of the Study:

  • To model the kinetics of drug binding to protein kinases within the EGFR signaling pathway.
  • To investigate how these binding kinetics influence the therapeutic potential of drugs targeting NSCLC.

Main Methods:

  • Computational modeling was employed to simulate drug-protein kinase interactions.
  • Kinetic parameters of drug binding were analyzed in the context of the EGFR pathway.

Main Results:

  • Drug binding kinetics were found to significantly influence therapeutic potential.
  • Fast binding kinetics demonstrated an advantage for most protein kinase targets, with notable exceptions.
  • Targeting certain protein kinases could paradoxically enhance pathway activity instead of attenuating it.
  • The half-maximal inhibitory concentration (IC50) was observed to be sensitive to drug binding kinetic parameters.

Conclusions:

  • Drug binding kinetics are a critical determinant of therapeutic efficacy in EGFR-driven NSCLC.
  • Therapeutic strategies should consider the specific kinetic profiles of drug-target interactions.
  • The potential for pathway enhancement necessitates careful selection of kinase targets and drug candidates.

More Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Pharmacodynamic Models: Emax Drug–Concentration Effect Model01:18

Pharmacodynamic Models: Emax Drug–Concentration Effect Model

The Emax drug-concentration effect model is central to pharmacodynamics in drug discovery and development. This model is predicated on the receptor occupancy theory, which posits that the effect of a drug is directly related to the number of receptors occupied by the drug and the resultant complex formation.The model describes the reversible interaction between a drug (C) and a receptor (R) to form a drug-receptor complex (RC). The kinetics of this interaction are quantified by an equation that...
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...